Biotest AG: Increase in sales of more than 5%
Biotest AG / Key word(s): Preliminary Results
15.02.2011 09:00
Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted
by DGAP - a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
Biotest: Increase in sales of more than 5%
Dreieich, 15 February 2011. According to preliminary and unaudited figures,
the Biotest Group (Plasma Proteins and Microbiological Monitoring) recorded
sales of EUR 461.2 million in the financial year 2010, an increase of 5.2%
compared to the previous year (EUR 438.6 million).
Earnings before interest and tax (EBIT) of the Group (Plasma Proteins,
Mikrobiological Monitoring, Biotherapeutics and Corporate) are
significantly lower with EUR 49.2 million compared to the previous year
EBIT of EUR 61.6 million. The reasons for this were predominantly
considerable price reductions for immunoglobulins and coagulation factors,
especially within the international business, as well as the unabsorbed
costs incurred in connection with the expansion of the production facility
in Boca Raton, Florida, USA.
The earnings before interest and taxes (EBIT) of the Biotest Group with its
Continuing and Discontinued business was EUR 67.7 million in the year 2010
and with this EUR 9.2 million higher compared to the previous year. This
increase of more than 15% results primarily of the profits from the sale of
the discontinued business with Medical Diagnostics division in January
2010.
Biotest will publish final results for the Financial Year 2010 on March
22th, 2011, the annual report will be published on the same day. The Annual
General Meeting of Biotest AG will take place on May 12th, 2011 in
Frankfurt a.M.
Biotest Aktiengesellschaft
The Executive Management Board
Biotest AG
Landsteinerstr. 5
D-63303 Dreieich
www.biotest.de
Disclaimer
This document contains forward-looking statements on overall economic
development as well as on the business, earnings, financial and assets
position of Biotest AG and its subsidiaries. These statements are based on
current plans, estimates, forecasts and expectations of the company and are
thus subject to risks and elements of uncertainty that could result in
significant deviation of actual developments from expected developments.
The forward-looking statements are only valid at the time of publication.
Biotest does not intend to update the forward-looking statements and
assumes no obligation to do so.
About Biotest
Biotest is a provider of pharmaceutical and biotherapeutic drugs as well as
reagents and systems for microbiology. With a value added chain that
extends from pre-clinical and clinical development to worldwide sales,
Biotest has specialised primarily in the areas of application of immunology
and haematology. In its Plasma Protein segment, Biotest develops and
markets immunoglobulins, coagulation factors and albumins based on human
blood plasma. These are used for diseases of the immune and haematopoietic
systems. In the Biotherapeutic segment, Biotest researches into the
clinical development of monoclonal antibodies, including in the indications
of rheumatoid arthritis and cancer of plasma cells. The products of the
Microbiological Monitoring segment are primarily used in hygiene
monitoring. Biotest has more than 1,900 employees worldwide. The preference
shares of Biotest AG are listed in the SDAX on the Frankfurt stock
exchange.
Securities' ID No., ISIN ordinary shares: 522720, DE0005227201
Securities' ID No., ISIN preference shares: 522723, DE0005227235
Listing: Prime Standard/Official traded
Frankfurt, Berlin, Düsseldorf, Hamburg, Stuttgart
15.02.2011 DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.medientreff.de and www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: Biotest AG
Landsteinerstraße 5
63303 Dreieich
Deutschland
Phone: 0 61 03 - 8 01-0
Fax: 0 61 03 - 8 01-150
E-mail: investor_relations@biotest.de
Internet: http://www.biotest.de
ISIN: DE0005227235, DE0005227201
WKN: 522723, 522720
Indices: SDAX
Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr
in Berlin, Düsseldorf, Hamburg, Stuttgart
End of Announcement DGAP News-Service
---------------------------------------------------------------------------
